Blood Test for Lung Cancer

(PROACT-LUNG Trial)

Recruiting at 39 trial locations

Overseen By Joye Choy, BS

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Freenome Holdings Inc.

Must not be taking: Chemotherapy, Immunotherapy, Biologics, others

Disqualifiers: Cancer therapy, Recent malignancy, Transplantation, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

20000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Who Is on the Research Team?

Victoria Sumner

Principal Investigator

Freenome Holdings Inc.

Are You a Good Fit for This Trial?

This trial is for people aged 50 or older who are current or former smokers with a history of smoking at least 20 packs a year. Participants must understand and agree to sign consent forms.

Inclusion Criteria

Are you 50 years or older?

You have been diagnosed with Lung Cancer

You have been diagnosed with Healthy Subjects

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Blood Sample Collection

Blood samples are collected from participants for the Freenome Multiomics Blood Test

1 day

1 visit (in-person)

Standard-of-Care Screening

Participants undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT)

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after screening, with data collection on diagnostic tests and procedures related to lung cancer diagnosis

24 months

What Are the Treatments Tested in This Trial?

Trial Overview The study is testing the effectiveness of a new blood test designed to detect lung cancer early in high-risk individuals, alongside their routine low-dose CT scans used for screening.

Who Is Running the Clinical Trial?

Freenome Holdings Inc.

Lead Sponsor

Trials

5

Recruited

78,500+